Use of avidin/biotin-liposome system for enhanced peritoneal drug delivery in an ovarian cancer model

International Journal of Pharmaceutics

Volumn 337, Issue 1-2, 2007, Pages 316-328

  Zavaleta, Cristina L ^a   Phillips, William T ^a   Soundararajan, Anuradha ^a   Goins, Beth A ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Avidin biotin system; Drug delivery; Liposomes; Nude rats; Ovarian cancer; Small animal imaging

Indexed keywords

AVIDIN; BIOTIN; LIPOSOME; PERTECHNETIC ACID TC 99M;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOPSY; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAPHRAGM; DRUG DELIVERY SYSTEM; DRUG UPTAKE; EUTHANASIA; FEMALE; IMAGING; INOCULATION; LYMPH NODE; LYMPHATIC SYSTEM; MEDIASTINUM; NONHUMAN; OMENTUM; OVARY CANCER; PERITONEUM; PRIORITY JOURNAL; RAT; SCINTIGRAPHY; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; AVIDIN; BIOTIN; CELL LINE, TUMOR; COLORING AGENTS; DELAYED-ACTION PREPARATIONS; DRUG COMPOUNDING; FEMALE; INJECTIONS, INTRAPERITONEAL; LIPIDS; LIPOSOMES; LYMPH NODES; MICE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; OVARIAN NEOPLASMS; PERITONEAL CAVITY; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RATS; RATS, NUDE; REPRODUCIBILITY OF RESULTS; ROSANILINE DYES; TECHNETIUM; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED; TRANSPLANTATION, HETEROLOGOUS;

EID: 34248582837     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2007.01.010     Document Type: Article

References (43)

1. Abu-Hijleh M.F., Habbal O.A., and Moqattash S.T. The role of the diaphragm in lymphatic absorption from the peritoneal cavity. J. Anat. 186 (1995) 453-467
2. American Cancer Society Website, 2006. Available from: http://www.cancer.org/docroot/CRI/CRI_2_3x.asp?dt=33 (cited 31 August 2006) (online).
3. American Type Culture Collection Web site, 2004. Available from: http://www.atcc.org/ (cited 17 February 2004) (online).
4. Banerjee R. Liposomes: applications in medicine. J. Biomater. Appl. 16 (2001) 3-21
5. Berek J.S., Bertelsen K., du Bois A., Brady M.F., Carmichael J., Eisenhauer E.A., Gore M., Grenman S., Hamilton T.C., Hansen S.W., Harper P.G., Horvath G., Kaye S.B., Luck H.J., Lund B., McGuire W.P., Neijt J.P., Ozols R.F., Parmar M.K., Piccart-Gebhart M.J., van Rijswijk R., Rosenberg P., Rustin G.J., Sessa C., Willemse P.H., et al. Advanced epithelial ovarian cancer: 1998 consensus statements. Ann. Oncol. 10 (1999) 87-92
6. Caliceti P., Chinol M., Roldo M., Veronese F.M., Semenzato A., Salmaso S., and Paganelli G. Poly(ethylene glycol)-avidin bioconjugates: suitable candidates for tumor pretargeting. J. Control. Rel. 83 (2002) 97-108
7. Cannistra S.A. Intraperitoneal chemotherapy comes of age. New Engl. J. Med. 354 (2006) 77-79
8. Chinol M., Casalini P., Maggiolo M., Canevari S., Omodeo E.S., Caliceti P., Veronese F.M., Cremonesi M., Chiolerio F., Nardone E., Siccardi A.G., and Paganelli G. Biochemical modifications of avidin improve pharmacokinetics and biodistribution, and reduce immunogenicity. Br. J. Cancer 78 (1998) 189-197
9. de Bree E., Witkamp A.J., and Zoetmulder F.A. Intraperitoneal chemotherapy for colorectal cancer. J. Surg. Oncol. 79 (2002) 46-61
10. Feldman G.B. Lymphatic obstruction in carcinomatous ascites. Cancer Res. 35 (1975) 325-332
11. Feldman G.B., Knapp R.C., Order S.E., and Hellman S. The role of lymphatic obstruction in the formation of ascites in a murine ovarian carcinoma. Cancer Res. 32 (1972) 1663-1666
12. Gadducci A., Cosio S., Conte P.F., and Genazzani A.R. Consolidation and maintenance treatments for patients with advanced epithelial ovarian cancer in complete response after first-line chemotherapy: a review of the literature. Crit. Rev. Oncol. Hematol. 55 (2005) 153-166
13. Gawronska B., Leuschner C., Enright F.M., and Hansel W. Effects of a lytic peptide conjugated to beta HCG on ovarian cancer: studies in vitro and in vivo. Gynecol. Oncol. 85 (2002) 45-52
14. Goldman E.R., Balighian E.D., Mattoussi H., Kuno M.K., Mauro J.M., Tran P.T., and Anderson G.P. Avidin: a natural bridge for quantum dot-antibody conjugates. J. Am. Chem. Soc. 124 (2002) 6378-6382
15. Grana C., Bartolomei M., Handkiewicz D., Rocca P., Bodei L., Colombo N., Chinol M., Mangioni C., Malavasi F., and Paganelli G. Radioimmunotherapy in advanced ovarian cancer: is there a role for pre-targeting with (90)Y-biotin?. Gynecol. Oncol. 93 (2004) 691-698
16. Green M.V., Seidel J., Vaquero J.J., Jagoda E., Lee I., and Eckelman W.C. High resolution PET, SPECT and projection imaging in small animals. Comput. Med. Imag. Graph. 25 (2001) 79-86
17. Kaye S.B. Future directions for the management of ovarian cancer. Eur. J. Cancer 37 (2001) S19-S23
18. Lecuru F., Guilbaud N., Agostini A., Augereau C., Vilde F., and Taurelle R. Description of two new human ovarian carcinoma models in nude rats suitable for laparoscopic experimentation. Surg. Endosc. 15 (2001) 1346-1352
19. Markman M. Intraperitoneal drug delivery of antineoplastics. Drugs 61 (2001) 1057-1065
20. Markman M. Intraperitoneal antineoplastic drug delivery: rationale and results. Lancet Oncol. 4 (2003) 277-283
21. McQuarrie S., Mercer J., Syme A., Suresh M., and Miller G. Preliminary results of nanopharmaceuticals used in the radioimmunotherapy of ovarian cancer. J. Pharm. Pharm. Sci. 7 (2005) 29-34
22. 99mTc-blue-biotin-liposome system. J. Pharm. Sci. 95 (2006) 207-224
23. National Cancer Institute Web site, 2005. Available from: http://nci.nih.gov/cancertopics/pdq/treatment/ovarianepithelial/Patient/page1 (cited 31 March 2005) (online).
24. Ogihara-Umeda I., Sasaki T., and Nishigori H. Active removal of radioactivity in the blood circulation using biotin-bearing liposomes and avidin for rapid tumour imaging. Eur. J. Nucl. Med. 20 (1993) 170-172
25. Phillips W.T., Rudolph A.S., Goins B., Timmons J.H., Klipper R., and Blumhardt R. A simple method for producing a technetium-99m-labeled liposome which is stable in vivo. Int. J. Radiat. Appl. Instrum. B 19 (1992) 539-547
26. Phillips W.T., Klipper R., and Goins B. Novel method of greatly enhanced delivery of liposomes to lymph nodes. J. Pharmacol. Exp. Ther. 295 (2000) 309-313
27. Phillips W.T., Medina L.A., Klipper R., and Goins B. A novel approach for the increased delivery of pharmaceutical agents to peritoneum and associated lymph nodes. J. Pharmacol. Exp. Ther. 303 (2002) 11-16
28. Reddy K.R. Controlled-release, pegylation, liposomal formulations: new mechanisms in the delivery of injectable drugs. Ann. Pharmacother. 34 (2000) 915-923
29. Sadzuka Y., Hirama R., and Sonobe T. Effects of intraperitoneal administration of liposomes and methods of preparing liposomes for local therapy. Toxicol. Lett. 126 (2002) 83-90
30. Sakahara H., and Saga T. Avidin-biotin system for delivery of diagnostic agents. Adv. Drug Deliv. Rev. 37 (1999) 89-101
31. Schneider J.G. Intraperitoneal chemotherapy. Obstet. Gynecol. Clin. North Am. 21 (1994) 195-212
32. Stebbing J., and Gaya A. Pegylated liposomal doxorubicin (Caelyx) in recurrent ovarian cancer. Cancer Treat. Rev. 28 (2002) 121-125
33. Stewart J.C. Colorimetric determination of phospholipids with ammonium ferrothiocyanate. Anal. Biochem. 104 (1980) 10-14
34. Syme A.M., McQuarrie S.A., Middleton J.W., and Fallone B.G. Dosimetric model for intraperitoneal targeted liposomal radioimmunotherapy of ovarian cancer micrometastases. Phys. Med. Biol. 48 (2003) 1305-1320
35. The National Ovarian Cancer Coalition Web site, 2005. Available from: http://www.ovarian.org/default.asp (cited 11 April 2005) (online).
36. Tsilibary E.C., and Wissig S.L. Light and electron microscope observations of the lymphatic drainage units of the peritoneal cavity of rodents. Am. J. Anat. 180 (1987) 195-207
37. Twardowski Z.J. History of peritoneal access development. Int. J. Artif. Organs 29 (2006) 2-40
38. 32P) versus observation after negative second-look laparotomy for stage III ovarian carcinoma: a randomized trial of the Gynecologic Oncology Group. J. Clin. Oncol. 21 (2003) 2849-2855
39. Watson E.E., Stabin M.G., Davis J.L., and Eckerman K.F. A model of the peritoneal cavity for use in internal dosimetry. J. Nucl. Med. 30 (1989) 2002-2011
40. Woodward P.J., Hosseinzadeh K., and Saenger J.S. From the archives of the AFIP: radiologic staging of ovarian carcinoma with pathologic correlation. Radiographics 24 (2004) 225-246
41. Xiao Z., McQuarrie S.A., Suresh M.R., Mercer J.R., Gupta S., and Miller G.G. A three-step strategy for targeting drug carriers to human ovarian carcinoma cells in vitro. J. Biotechnol. 94 (2002) 171-184
42. 32P or intravenous cyclophosphamide and cisplatin-a gynecologic oncology group study. J. Clin. Oncol. 21 (2003) 4350-4355
43. Zavaleta C.L., Phillips W.T., Bradley Y.C., Jerabek P.A., and Goins B.A. Use of MicroPET to non-invasively monitor the development of an intraperitoneal ovarian xenograft model in nude rats. J. Nucl. Med. 46 (2005) 235